Medicaid prescriptions for weight loss-approved GLP-1 medications fell sharply after four states ended coverage of the drugs, according to a new study led by researchers at the University of Pittsburgh. The findings, published today in JAMA , demonstrate how state coverage decisions can have an immediate and substantial effect on access to these medications.
On Jan. 1, 2026, California, New Hampshire, Pennsylvania and South Carolina withdrew Medicaid coverage for GLP-1 drugs prescribed for weight loss. In those states, the number of quarterly prescriptions fell by approximately 84% relative to changes in 10 states that maintained coverage.
"These immediate declines corroborate what we saw clinically. Many of my Medicaid-insured patients prescribed GLP-1s for weight management lost coverage," said lead author Bryant Shuey, M.D., M.P.H., assistant professor of medicine at Pitt. "When patients abruptly stop taking these medications, they are at risk of worsening cardiometabolic health related to weight regain."
GLP-1 medications mimic a naturally occurring hormone that helps regulate appetite and blood sugar. Although Medicaid programs generally are required to cover most outpatient drugs, federal law allows states to exclude medications used for weight loss. Since 2022, 17 state Medicaid programs have elected to cover U.S. Food and Drug Administration-approved GLP-1 medications for weight loss, frequently using prior authorization requirements to manage access and costs.
For the study, researchers analyzed Medicaid prescription data from all 50 states and Washington, D.C., between January 2022 and March 2026. The data included prescriptions reimbursed through both fee-for-service Medicaid and Medicaid managed care programs. Nationally, quarterly prescriptions for weight loss-approved GLP-1 medications increased by 5,858% between the first quarter of 2022 and the first quarter of 2026. Use grew most rapidly in states that provided Medicaid coverage for the medications. During the same time, prescriptions for GLP-1 medications for diabetes grew by a relatively modest 150%.
The researchers then examined prescription changes in the four states that withdrew coverage compared with changes in 10 states that maintained coverage throughout the study's comparison period. Between the final quarter of 2025 and the first quarter of 2026, weight loss-approved GLP-1 prescriptions fell from 2,914 to 421 per 100,000 Medicaid beneficiaries in states that ended coverage. In states that maintained coverage, prescriptions declined more modestly, from 3,006 to 2,758 per 100,000 beneficiaries. The largest decline occurred in Pennsylvania, where the prescription rate fell by 95.5%. Prescription rates decreased by 88% in New Hampshire, 75.2% in California and 60.8% in South Carolina.
Based on typical prescription-filling patterns, the researchers estimate that approximately 175,500 to 526,600 fewer Medicaid beneficiaries across the four states may have filled prescriptions for weight loss-approved GLP-1 medications after coverage ended. Because the data tracked prescriptions rather than individual patients, the researchers could not determine the exact number of people affected or whether patients obtained the medications through private payment or other sources.
"It is not surprising that abruptly ending drug coverage creates major disruptions in care," said senior author Timothy S. Anderson, M.D., M.A.S., associate professor of medicine at Pitt. "Medicaid covers 20% of Americans and state Medicaid budgets are shrinking, which will continue to put high-cost therapies further out of reach unless drug costs come down or federal support for Medicaid changes."
The researchers found no statistically significant corresponding increase in the use of GLP-1 medications approved for diabetes in states that withdrew weight loss coverage. This suggests that patients did not broadly shift to diabetes-approved versions of the medications through Medicaid, although the available data could not track individual patients or prescriptions. Further research is needed to determine whether some patients were able to maintain access under another covered medical indication, such as sleep apnea.
The study was observational and could not measure patients' health outcomes, privately paid prescriptions or the effects of every change to state prior authorization policies. Other coverage changes may have contributed to the findings. The results nevertheless show a strong association between the withdrawal of Medicaid coverage and reduced use of weight loss-approved GLP-1 medications. The authors said clinicians caring for patients affected by coverage changes should monitor their cardiometabolic risk factors and discuss other approaches to weight management and diabetes prevention.
"While evidence-based weight loss approaches such as diet-focused interventions are available, it often requires greater effort to identify those covered by insurance," said Shuey. "Patients and clinicians should explore these options while monitoring cardiometabolic health and addressing potential risks."
Explore the full study and related resources:
- "Glucagon-Like Peptide-1 Utilization Following Withdrawal of Medicaid Coverage for Weight Loss" |JAMA
- Center for Research on Health Care | University of Pittsburgh
- Center for Pharmaceutical Policy and Prescribing | University of Pittsburgh
Co-authors include Jing Luo, M.D., M.P.H., of Pitt; James Franklin Wharam, M.D., M.P.H., of Duke University; and Elizabeth Nguyen, B.S., of the Geisinger Commonwealth School of Medicine.
The research was supported by the National Institute on Drug Abuse (K23DA062822), the National Institute on Aging (K76AG074878) and the National Institute on Alcohol Abuse and Alcoholism (R01AA029819).